Abstract #4009

Magnetic resonance spectroscopy-based metabolic biomarkers of IDH1 mutant glioma in response to temozolomide therapy

Elavarasan Subramani¹, Lydia M Le Page¹, Russell O. Pieper^2,3, and Sabrina M Ronen^1,3

¹Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²Department of Neurological Surgery, Helen Diller Research Center, University of California, San Francisco, San Francisco, CA, United States, ³Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA, United States

The alkylating agent temozolomide (TMZ), previously used only in the treatment of high-grade glioblastoma, is now being considered for the treatment of low-grade glioma that are driven by mutations in the cytosolic isocitrate dehydrogenase 1 (IDH1) gene. However, early detection of response remains a challenge. ¹H magnetic resonance spectroscopy-based metabolic profiling of cells genetically engineered to express mutant IDH1 and treated with TMZ showed significant alterations in metabolites majorly related to the tricarboxylic acid cycle, pyruvate metabolism and the pentose phosphate pathway. These findings hold potential for assessing response of IDH1 mutant cells to TMZ therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here